Hoth Therapeutics, Inc. (HOTH)
After hours:
- PR Newswire
Hoth Therapeutics Announces Promising Preclinical Results for Alzheimer's Drug HT-ALZ
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing innovative treatments for unmet medical needs, today announced encouraging preclinical results for its investigational Alzheimer's drug, HT-ALZ. In a recent study using Alzheimer's model mice treated with varying doses of HT-ALZ, significant reductions in astrocyte activity were observed in key areas of the brain, suggesting a potential link between reduced reactive astrocytes, and improved cognitive functi
- Zacks
Hoth Stock Up as Lead Drug Heals Skin Toxicities in Cancer Patient
HOTH stock soars on superior efficacy data from the first patient treated with the lead candidate, HT-001, suffering from EGFRI-related skin toxicities.
- PR Newswire
Hoth Therapeutics Announces Expansion of Clinical Sites for HT-001 Phase 2a Trial
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced today that it has received Institutional Review Board approval from the Montefiore Medical Center and the Dana-Farber Cancer Institute to proceed with its First-in-Human (FIH) Phase 2a clinical trial of HT-001 for the treatment of skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors (EGFRi).
